Accolade, Inc.

Accolade — Investor Presentation (June 2023)

31 slides from Accolade's investor presentation, Jun 29, 2023

  1. Slide 1: Accolade Inc. Investor Presentation

    Accolade Inc. Investor Presentation

  2. Slide 2: Forward-looking statements

    This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b

  3. Slide 3: Building a customer-obsessed, nationwide healthcare delivery company

    Building a customer-obsessed, nationwide healthcare delivery company

  4. Slide 4: An imperfect system

    75% of healthcare spending is on chronic health conditions* * cdc.gov An imperfect system 80% of the US lacks adequate The healthcare system is reactive access to healthcare* * goodrx.com Healthcare access is inadequate Investments alone aren’t improving the experience $29B in digital health startup

  5. Slide 5: A Truly Powerful, Personalized Healthcare Platform

    A Truly Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based Accolade Accolade Accolade Trusted Advocacy Expert MD Care Partners Personalized, trusted Real-time expert Same-day access to Leveraging guidance and consultations for virtual primary and Accolade’s core educatio

  6. Slide 6: A differentiated service

    A differentiated service Flawless experience Clinical population health strategy Scale Ecosystem collaboration

  7. Slide 7: Engagement and Clinical Approach Drives Results

    Engagement and Clinical Approach Drives Results % Assisted %Provider Engagem ent Total Contacts 25 100% 98% 94% 93% 90% 79% 20 80% 70% 62% 15 60% 52% 42% 40% 10 40% 29% 20% 20% 5 0% 0 0 - $2500 $2.5k - $10k $10k to $25k $25k t o $50k $50k t o $100k $100k+ Low-spend Families Middle-spend Families Hig

  8. Slide 8: Accolade is Engineered to Care

    Predictive Engagement Accolade is Engineered to Care Proactive Care Addressing Barriers

  9. Slide 9: Engineered to Care: Technology and People Deliver

    Engineered to Care Technology and People Deliver Early and Repeat Expert Physicians Engagement Diagnosis & Treatment Review Member Insights and care recommendation 69% PCPs & Therapists Acute, Chronic & Preventive Ongoing data analysis Care team interaction and influence Registered Member Nurses Car

  10. Slide 10: True Health Actions

    Case Management Care Navigation Care Decision Support True Health Actions Disability, Family & Financial Navigation Wellness Support Healthcare Literacy

  11. Slide 11: True Health Actions Drive Personalized Experience

    True Health Actions Drive Personalized FLCT Experience A Concept – Member A Health Snapshot B Deployed – Alerts B C Deployed – True Health Action Recommendations C

  12. Slide 12: True Health Actions Create a Personalized Digital Experience

    True Health Actions Create a Personalized Digital Experience Accolade Driven user need “For you” Support call(s) to action (True Health Actions) Member Driven user need “Ways we can help” Bring User Need resolution paths to front

  13. Slide 13: Accolade's Advantages for the Healthcare Ecosystem

    Accolade’s Advantages for the Healthcare Ecosystem Front Line Care Teams Data set End to end reporting

  14. Slide 14: Representative customers and partners

    5 (representative) net wpthink Q, MERITAIN" me Quilibrium oP Proguny HEALTH 3 businessolver CARROT headspace @Yxss health. VSP... SLabCorp Qj, wwsen WebMD Sn PI DENTAL Benefit Q Harbor Cvs we UMR C carrumhealth CAREMARR | @ AmeriBen < ) oo sedgwick vivante © Brightside PLANS DURCE iori ) EQUIP i rw)

  15. Slide 15: Improved Outcomes Across Conditions

    Improved Outcomes Across Conditions No Received 1+ Improvement Interventions Interventions Musculoskeletal AVOIDABLE ER VISITS 57% members engaged 44% received 1+ Interventions 15% 13% -13% Depression or Anxiety OUTPATIENT BH VISITS (per member per year) 47% members engaged 35% received 1+ Intervent

  16. Slide 16: Compelling Growth Strategy

    Compelling Growth Strategy Grow customer base Underpenetrated market of 30,000+ self- and fully insured employers Retain and expand Grow relationships through add-on sales such as Accolade Care, Accolade Expert MD, TPE customer Leverage generative AI, machine learning, predictive analytics, and mult

  17. Slide 17: Financials

    Financials 17

  18. Slide 18: Platform built for Growth, Scale & Profitability

    Platform built for Growth, Scale & Profitability Strategic hub for personalized healthcare driving customer ROI Growth driven by differentiated revenue mix addressing large TAM High revenue visibility and customer diversification Integrated platform enables scale, utilization, and margin expansion C

  19. Slide 19: Accelerating Accolade's Innovation

    Accelerating Accolade’s Innovation Continuous investment in clinical transformation and operational excellence Created a Proven Launched Intelligent Launched Launched Mental Acquired 2nd.MD - Acquired PlushCare - Introduced High Touch, High Provider Matching Accolade COVID Health Integrated Expert M

  20. Slide 20: Significantly Expanded Addressable Market

    Significantly Expanded Addressable Market $216 billion TAM 900 Customers 800+ $170B 800 Primary Care 700 600+ 600 500 $22B 400 Expert Medical Opinion 300 200 $24B 112 Navigation & Advocacy 100 54 15 20 0 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 (w M&A) 20

  21. Slide 21: Consistent growth and progress toward profitability

    Consistent growth and progress toward profitability Revenue GR ~$412M 33% C A $363M $310M $170M $133M FY20 FY21 FY22 FY23 FY24P Adjusted EBITDA (Loss) & Adjusted OpEx as % of revenue 70% 61% 60% 57% ~50% -16% -14% -10% -25% -2% FY20 FY21 FY22 FY23 FY24P FYE = February Accolade ©2023 21

  22. Slide 22: Customer and revenue diversification

    Customer and revenue diversification FY23 FY20 800+ customers • 200+ Advocacy • 600+ EMO • 54 customers • Launched eVPC in past year • 6 customers ~ 75% of • >10% with >1 core offering revenue • No 5% customer in FY24P • Broad industry diversification Accolade ©2023 22

  23. Slide 23: Strong visibility to growth and profitability

    Strong visibility to growth and profitability Targeting $1 billion revenue and 10-15% AEBITDA in FY29 Revenue AEBITDA $1B+ Horizon 2 Key drivers • Integrated healthcare platform Horizon 1 R o Advocacy AG C o Primary Care and mental health 2 0% ~$500M o Expert Medical Opinion 10-15% o Trusted Partner

  24. Slide 24: Financial Targets and Goals (Non-GAAP)

    Financial Targets and Goals (Non-GAAP) Long-Term Goals Adj. Gross Margin 50-55% P&T as 13-17% % of Rev. Adj. Operating S&M as Expenses 15-20% % of Rev. G&A as 7-9% % of Rev. Adj. EBITDA Margin 15-20% Accolade ©2023 24

  25. Slide 25: Growth, Scale & Profitability

    Growth, Scale & Profitability Highly diversified revenue mix Expanding margins and operating leverage One Accolade driving operational efficiencies Attractive and improving unit economics Clear vision toward $1B+ revenue and target financial model Accolade ©2023 25

  26. Slide 26: Appendix

    Appendix

  27. Slide 27: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA

    Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjus

  28. Slide 28: Adjusted EBITDA (Loss) Reconciliation

    Adjusted EBITDA (Loss) Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 2023 Net Loss $ (56,496) $ (51,365) $ (50,652) $ (123,124) $ (459,650) Adjusted for: Interest expense (income), net 2,374 2,925 3,724 2,905 (255) Income tax expense (benefit) 55 129 4 (5,63

  29. Slide 29: Adjusted Gross Margin Reconciliation

    Adjusted Gross Margin Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 2023 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 $ 363,142 Less: Cost of revenue, excluding depreciation and (60,568) (73,685) (93,673) (169,019) (198,905) amortization Gross Profit, excl

  30. Slide 30: Adjusted Operating Expense Reconciliation

    Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 2023 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 $ 363,142 Operating Expenses 88,220 107,026 123,462 266,727 627,751 Less: Depreciation and amortization (9,391) (8,516) (8,212) (42,6

  31. Slide 31: Accolade

    Accolade PERSONALIZED HEALTHCARE

Accolade — Investor Presentation (June 2023) on 6ix